ABBV vs INMD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.
Compare Another Pair
Related Comparisons
ABBV vs INMD: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and InMode Ltd. (INMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.